Pneumococcal conjugate vaccine, 13-valent

PBAC's latest decision on Pneumococcal conjugate vaccine, 13-valent: Recommended (2016). Considered for Prevention of pneumococcal disease (community-acquired pneumonia and invasive pneumococcal disease) in pneumococcal vaccine-naive non-Indigenous adults aged 65 years and over, and pneumococcal vaccine-naive Indigenous adults aged 50 years and over.

Eligible population

Pneumococcal vaccine-naive non-Indigenous adults aged 65 years and over, and pneumococcal vaccine-naive Indigenous adults aged 50 years and over.

Therapy area

Vaccines

Line of therapy

Not applicable

Evidence base

RCT

Primary endpoint

Vaccine-type pneumococcal community-acquired pneumonia and vaccine-type invasive pneumococcal disease

Pivotal trial size

84,496 patients

Key trials

CAPiTA, Alfageme 2006, Furumoto 2008, Kawakami 2010, Maruyama 2010, Örtqvist 1998, Menzies 2014, B1851138, B1851020

Comparator

23-valent pneumococcal polysaccharide vaccine (23vPPV)

Economic model

CUA

ICER note

Cost-minimisation analysis; PBAC recommended 13vPCV on basis of cost-minimisation to 23vPPV at July 2015 meeting. Current submission (July 2016) sought to demonstrate cost-effectiveness but economic model details are incomplete in the provided text; ICER values not stated in excerpt.

Submission history

• Mar 2015: Recommended with restriction · Restricted
• Jul 2015: Not recommended · Not applicable
• Jul 2016: Recommended · Restricted

Similar precedents

• Pneumococcal polysaccharide conjugate vaccine, 13-valent
  similarity 0.94
• Pneumococcal conjugate vaccine 13-valent (13vpcv) and pneumococcal polysaccharide vaccine 23-valent (23vppv)
  similarity 0.90
• Pneumococcal polysaccharide conjugate 13-valent
  similarity 0.87
• Pneumococcal polysaccharide conjugate vaccine, 20-valent
  similarity 0.82
• Pneumococcal conjugate vaccine, 15-valent
  similarity 0.79
• Pneumococcal conjugate vaccine, 20-valent
  similarity 0.78